159 related articles for article (PubMed ID: 8819130)
1. Determinants of acute regional toxicity following isolated limb perfusion for melanoma.
Thompson JF; Eksborg S; Kam PC; Ingvar C; Yau DF; Lai DT; Ramzan I
Melanoma Res; 1996 Jun; 6(3):267-71. PubMed ID: 8819130
[TBL] [Abstract][Full Text] [Related]
2. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and morbidity of isolated limb perfusion.
Vrouenraets BC; Klaase JM; Nieweg OE; Kroon BB
Semin Surg Oncol; 1998; 14(3):224-31. PubMed ID: 9548605
[TBL] [Abstract][Full Text] [Related]
4. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
5. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
[TBL] [Abstract][Full Text] [Related]
6. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
Hoekstra HJ; Veerman K; van Ginkel RJ
J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
[TBL] [Abstract][Full Text] [Related]
7. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
[TBL] [Abstract][Full Text] [Related]
8. Systemic toxicity after isolated limb perfusion with melphalan for melanoma.
Sonneveld EJ; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; van Dongen JA; Kroon BB
Eur J Surg Oncol; 1996 Oct; 22(5):521-7. PubMed ID: 8903497
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
10. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
11. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.
Thompson JF; Gianoutsos MP
World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of a double perfusion schedule using high dose hyperthermia and melphalan sequentially in extensive melanoma of the lower limb.
Noorda EM; Vrouenraets BC; Nieweg OE; Klaase JM; van der Zee J; Kroon BB
Melanoma Res; 2003 Aug; 13(4):395-9. PubMed ID: 12883366
[TBL] [Abstract][Full Text] [Related]
13. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; van Geel AN; Eggermont AM
Cancer; 2006 Jan; 106(1):156-62. PubMed ID: 16323177
[TBL] [Abstract][Full Text] [Related]
14. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma.
Thompson JF; Lai DT; Ingvar C; Kam PC
Melanoma Res; 1994 Mar; 4 Suppl 1():45-50. PubMed ID: 8038596
[TBL] [Abstract][Full Text] [Related]
15. Melphalan dosing regimens for management of recurrent melanoma by isolated limb perfusion: application of a physiological pharmacokinetic model based on melphalan distribution in the isolated perfused rat hindlimb.
Wu ZY; Smithers BM; Roberts MS
Melanoma Res; 1997 Jun; 7(3):252-64. PubMed ID: 9195565
[TBL] [Abstract][Full Text] [Related]
16. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases.
Pace M; Gattai R; Mascitelli EM; Millanta L
J Surg Oncol; 2011 Dec; 104(7):718-23. PubMed ID: 21721008
[TBL] [Abstract][Full Text] [Related]
17. Induction of systemic serum procalcitonin and cardiocirculatory reactions after isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan.
Kettelhack C; Hohenberger P; Schulze G; Kilpert B; Schlag PM
Crit Care Med; 2000 Apr; 28(4):1040-6. PubMed ID: 10809279
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb perfusion for malignant melanoma.
Alexander HR; Fraker DL; Bartlett DL
Semin Surg Oncol; 1996; 12(6):416-28. PubMed ID: 8914206
[TBL] [Abstract][Full Text] [Related]
19. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan.
Vrouenraets BC; in't Veld GJ; Nieweg OE; van Slooten GW; van Dongen JA; Kroon BB
Eur J Surg Oncol; 1999 Oct; 25(5):503-8. PubMed ID: 10529261
[TBL] [Abstract][Full Text] [Related]
20. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
